Redx Pharma Plc (LON:REDX) Insider Lisa Anson Buys 115,000 Shares

Redx Pharma Plc (LON:REDX) insider Lisa Anson purchased 115,000 shares of the firm’s stock in a transaction on Tuesday, April 16th. The shares were acquired at an average price of GBX 9 ($0.11) per share, with a total value of £10,350 ($12,884.35).

Lisa Anson also recently made the following trade(s):

• On Thursday, April 11th, Lisa Anson purchased 399,000 shares of Redx Pharma stock. The shares were acquired at an average price of GBX 8 ($0.10) per share, with a total value of £31,920 ($39,736.09).

Redx Pharma Stock Performance

Shares of REDX stock opened at GBX 12.75 ($0.16) on Friday. The firm has a market capitalization of £49.60 million, a PE ratio of -127.50 and a beta of -0.53. The firm has a fifty day simple moving average of GBX 16.75 and a two-hundred day simple moving average of GBX 21.11. The company has a current ratio of 1.11, a quick ratio of 1.93 and a debt-to-equity ratio of 527.00. Redx Pharma Plc has a 12 month low of GBX 4 ($0.05) and a 12 month high of GBX 37.90 ($0.47).

About Redx Pharma

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.